Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

  • Anebulo Pharmaceuticals Inc ANEB has announced topline data from Part A of an ongoing Phase 2 trial of ANEB-001 to treat acute cannabinoid intoxication (ACI). 
  • Part A was a 60-subject trial designed to evaluate the effectiveness of a single dose of ANEB-001 in healthy subjects challenged with delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis. 
  • The data demonstrated a statistically significant reduction in key symptoms of ACI, with only 10% of subjects in the 50 mg ANEB-001 group and 30% in the 100 mg group reporting feeling high compared to 75% of subjects in the placebo group.
  • ANEB-001 was well tolerated in these healthy volunteers. 
  • Preliminary safety data showed all adverse events were mild and transient, except for one subject in the 50 mg ANEB-001 group who experienced moderate nausea and vomiting.
  • Subjects challenged with THC and treated with placebo showed substantial CNS effects, including feeling high, decreased alertness, increased body sway, and increased heart rate. 
  • The company plans to initiate Part B of the study by the end of Q3 2022 to evaluate lower doses of ANEB-001. 
  • Preparations are ongoing for an observational study on ACI subjects in the emergency department. Submission of an Investigational New Drug application for ANEB-001 to initiate U.S. trials is anticipated by the end of 2022.
  • Price Action: ANEB shares are up 17.21% at $6.30 premarket on the last check Tuesday.

Posted In: Briefswhy it's movingBiotechNewsHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.